Introduction: The aim of this study is to describe our experience on portal vein embolization (PVE) without cleaning the left lobe, emphasizing liver hypertrophy and the behavior of the contralateral metastasis. Methods: Non-concurrent cohort study at a single center. Patients who underwent PVE before liver resection with bilobar metastases between 2016 and 2020 were included. Results: Fifteen patients were included. The median age was 67.6 years. In 13 patients (86.7%) the diagnosis was colorectal liver metastasis and neuroendocrine tumor in 2 (13.3%). Eleven patients (73.3%) had right PVE alone and 4 (26.7%) had right plus segment IV embolization. One patient (6.7%) had a complication after PVE (metastasis bleeding). Median time between PVE and volumetry was 5.3 (IQR,4.7-7.1) weeks. The median change of hypertrophy was 46.2% (IQR, 35.6-72.4). The median kinetic growth rate (KGR) was 1.9% per week (IQR,1.1-2.6). Median metastasis diameter in the FLR pre and post-PVE was 18 mm (IQR,11-22) and 12 mm (IQR,8-14), respectively. This diameter decreased by 73.3% (n=11) after PVE. Three patients could not undergo liver resection (3/15,20%), only two of them due to tumor growth in FLR. One patient (6.7%) had post-hepatectomy liver failure. The median follow-up was 25.6 (5.8-51.3) months, with an overall survival rate of 81% at 48 months from PVE. Conclusions: PVE is safe and effective in promoting an adequate FLR, without favoring the accelerated growth of tumor lesions in the non-embolized remnant liver. This approach allows continued chemotherapy during the hypertrophy period and safe resection of bilobar metastasis in one stage.